Manufacture and Sale of Medicines
Chong Kun Dang Pharmaceutical Corp. is one of Korea’s leading pharmaceutical companies with strong capabilities in the domestic market. Its portfolio includes prescription medicines for hypertension, dyslipidemia, and diabetes, such as Telminuvo®, Lipilou®, and Duvie®, as well as over-the-counter medicines and consumer healthcare products, including household insecticides and hair dyes.

Global Business Presence
Chong Kun Dang is expanding its global presence through strategic products in therapeutic areas such as immunosuppression, oncology, and infectious diseases. To strengthen its glocalization strategy, which combines global capabilities with local expertise, the company opened a representative office in Vietnam in 2012 and established a joint venture in Indonesia in 2015.

Licensing and Tech Transfer
Chong Kun Dang actively pursues in-licensing opportunities for novel therapies that offer improved treatment options for chronic conditions such as diabetes and cardiovascular disease, as well as for cancer and neurological disorders with significant unmet medical needs.
Building on the successful development of Duvie®, a novel treatment for type 2 diabetes, Chong Kun Dang is expanding its global presence through its best-in-class oncology pipelines, including CKD-516 and CKD-581, and its dyslipidemia therapies, beginning with neighboring Asian markets.
The company has also established an in-house technology platform for the development of selective HDAC6 inhibitors with novel mechanisms of action. Through strategic business diversification, Chong Kun Dang is actively preparing for further expansion into global markets, with a particular focus on autoimmune diseases, neurological disorders, and cancer.

Business Alliance
Supported by its long-standing presence in the Korean pharmaceutical industry and its strong sales and marketing capabilities, Chong Kun Dang has established numerous strategic alliances with leading multinational pharmaceutical companies across a wide range of therapeutic areas.
Over the past decade, Chong Kun Dang has formed partnerships with global companies such as Bayer, Roche, Allergan, Pfizer, and Amgen. These partnerships, together with the company’s robust portfolio of innovative medicines across multiple therapeutic areas, have further strengthened Chong Kun Dang’s leadership in the Korean pharmaceutical market.
Chong Kun Dang will continue to pursue mutual growth and value creation through strategic global partnerships.